Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study

Trial Profile

Effects of ivabradine on cardiovascular events in patients with moderate-to-severe chronic heart failure and left ventricular systolic dysfunction. A three-year randomised double-blind placebo-controlled international multicentre study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Acronyms SHIFT
  • Sponsors IRIS; Servier
  • Most Recent Events

    • 24 Apr 2023 Results of post-hoc analysis assessing the clinical significance of the time durations of heart rate reduction and the significant treatment effect on outcomes among patients with heart failure and reduced ejection fraction, published in the European Journal of Heart Failure.
    • 27 Feb 2021 Results of meta-analysis of 6 studies, published in the Clinical Cardiology.
    • 18 Nov 2019 Results assessing impact on the outcome adjudication of the Systolic Heart failure treatment, presented at the American Heart Association Scientific Sessions 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top